These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36921598)

  • 1. Engineered cardiac tissue model of restrictive cardiomyopathy for drug discovery.
    Wang BZ; Nash TR; Zhang X; Rao J; Abriola L; Kim Y; Zakharov S; Kim M; Luo LJ; Morsink M; Liu B; Lock RI; Fleischer S; Tamargo MA; Bohnen M; Welch CL; Chung WK; Marx SO; Surovtseva YV; Vunjak-Novakovic G; Fine BM
    Cell Rep Med; 2023 Mar; 4(3):100976. PubMed ID: 36921598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene correction and overexpression of TNNI3 improve impaired relaxation in engineered heart tissue model of pediatric restrictive cardiomyopathy.
    Hasegawa M; Miki K; Kawamura T; Takei Sasozaki I; Higashiyama Y; Tsuchida M; Kashino K; Taira M; Ito E; Takeda M; Ishida H; Higo S; Sakata Y; Miyagawa S
    Dev Growth Differ; 2024 Feb; 66(2):119-132. PubMed ID: 38193576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired Relaxation in Induced Pluripotent Stem Cell-Derived Cardiomyocytes with Pathogenic
    Wang R; Hasegawa M; Suginobe H; Yoshihara C; Ishii Y; Ueyama A; Ueda K; Hashimoto K; Hirose M; Ishii R; Narita J; Watanabe T; Kawamura T; Taira M; Ueno T; Miyagawa S; Ishida H
    J Am Heart Assoc; 2024 Mar; 13(6):e032375. PubMed ID: 38497452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROD2 domain filamin C missense mutations exhibit a distinctive cardiac phenotype with restrictive/hypertrophic cardiomyopathy and saw-tooth myocardium.
    Bermúdez-Jiménez FJ; Carriel V; Santos-Mateo JJ; Fernández A; García-Hernández S; Ramos KA; Piqueras-Flores J; Cabrera-Romero E; Barriales-Villa R; de la Higuera Romero L; Alcalá López JE; Gimeno Blanes JR; Sánchez-Porras D; Campos F; Alaminos M; Oyonarte-Ramírez JM; Álvarez M; Tercedor L; Brodehl A; Jiménez-Jáimez J
    Rev Esp Cardiol (Engl Ed); 2023 May; 76(5):301-311. PubMed ID: 35952944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Mutation in
    Tucker NR; McLellan MA; Hu D; Ye J; Parsons VA; Mills RW; Clauss S; Dolmatova E; Shea MA; Milan DJ; Scott NS; Lindsay M; Lubitz SA; Domian IJ; Stone JR; Lin H; Ellinor PT
    Circ Cardiovasc Genet; 2017 Dec; 10(6):. PubMed ID: 29212899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of Filamin C Results in Altered Proteostasis, Cardiomyopathy, and Arrhythmias.
    Ohiri JC; Dellefave-Castillo L; Tomar G; Wilsbacher L; Choudhury L; Barefield DY; Fullenkamp D; Gacita AM; Monroe TO; Pesce L; Blancard M; Vaught L; George AL; Demonbreun AR; Puckelwartz MJ; McNally EM
    J Am Heart Assoc; 2024 May; 13(10):e030467. PubMed ID: 38761081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pathogenic variants in filamin C identified in pediatric restrictive cardiomyopathy.
    Schubert J; Tariq M; Geddes G; Kindel S; Miller EM; Ware SM
    Hum Mutat; 2018 Dec; 39(12):2083-2096. PubMed ID: 30260051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for
    Kondo T; Higo S; Shiba M; Kohama Y; Kameda S; Tabata T; Inoue H; Okuno S; Ogawa S; Nakamura S; Takeda M; Ito E; Li J; Liu L; Kuramoto Y; Lee JK; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Circ Genom Precis Med; 2022 Oct; 15(5):e003522. PubMed ID: 35861968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac Fibroblasts Play Pathogenic Roles in Idiopathic Restrictive Cardiomyopathy.
    Tsuru H; Ishida H; Narita J; Ishii R; Suginobe H; Ishii Y; Wang R; Kogaki S; Taira M; Ueno T; Miyashita Y; Kioka H; Asano Y; Sawa Y; Ozono K
    Circ J; 2021 Apr; 85(5):677-686. PubMed ID: 33583869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restrictive cardiomyopathy: from genetics and clinical overview to animal modeling.
    Chintanaphol M; Orgil BO; Alberson NR; Towbin JA; Purevjav E
    Rev Cardiovasc Med; 2022 Mar; 23(3):108. PubMed ID: 35345275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Filamin C Deficiency Impairs Sarcomere Stability and Activates Focal Adhesion Kinase through PDGFRA Signaling in Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Gao S; He L; Lam CK; Taylor MRG; Mestroni L; Lombardi R; Chen SN
    Cells; 2024 Feb; 13(3):. PubMed ID: 38334670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutations in FLNC are Associated with Familial Restrictive Cardiomyopathy.
    Brodehl A; Ferrier RA; Hamilton SJ; Greenway SC; Brundler MA; Yu W; Gibson WT; McKinnon ML; McGillivray B; Alvarez N; Giuffre M; Schwartzentruber J; ; Gerull B
    Hum Mutat; 2016 Mar; 37(3):269-79. PubMed ID: 26666891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human iPSC-engineered cardiac tissue platform faithfully models important cardiac physiology.
    de Lange WJ; Farrell ET; Kreitzer CR; Jacobs DR; Lang D; Glukhov AV; Ralphe JC
    Am J Physiol Heart Circ Physiol; 2021 Apr; 320(4):H1670-H1686. PubMed ID: 33606581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diastolic dysfunction and thin filament dysregulation resulting from excitation-contraction uncoupling in a mouse model of restrictive cardiomyopathy.
    Davis J; Yasuda S; Palpant NJ; Martindale J; Stevenson T; Converso K; Metzger JM
    J Mol Cell Cardiol; 2012 Sep; 53(3):446-57. PubMed ID: 22683325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pivotal Role of Non-cardiomyocytes in Electromechanical and Therapeutic Potential of Induced Pluripotent Stem Cell-Derived Engineered Cardiac Tissue.
    Iseoka H; Miyagawa S; Fukushima S; Saito A; Masuda S; Yajima S; Ito E; Sougawa N; Takeda M; Harada A; Lee JK; Sawa Y
    Tissue Eng Part A; 2018 Feb; 24(3-4):287-300. PubMed ID: 28498040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human engineered cardiac tissue model of hypertrophic cardiomyopathy recapitulates key hallmarks of the disease and the effect of chronic mavacamten treatment.
    Wang K; Schriver BJ; Aschar-Sobbi R; Yi AY; Feric NT; Graziano MP
    Front Bioeng Biotechnol; 2023; 11():1227184. PubMed ID: 37771571
    [No Abstract]   [Full Text] [Related]  

  • 17. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes derived from human-induced pluripotent stem cells.
    Pioner JM; Guan X; Klaiman JM; Racca AW; Pabon L; Muskheli V; Macadangdang J; Ferrantini C; Hoopmann MR; Moritz RL; Kim DH; Tesi C; Poggesi C; Murry CE; Childers MK; Mack DL; Regnier M
    Cardiovasc Res; 2020 Feb; 116(2):368-382. PubMed ID: 31049579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic recapitulation and correction of desmoglein-2-deficient cardiomyopathy using human-induced pluripotent stem cell-derived cardiomyocytes.
    Shiba M; Higo S; Kondo T; Li J; Liu L; Ikeda Y; Kohama Y; Kameda S; Tabata T; Inoue H; Nakamura S; Takeda M; Ito E; Takashima S; Miyagawa S; Sawa Y; Hikoso S; Sakata Y
    Hum Mol Genet; 2021 Jul; 30(15):1384-1397. PubMed ID: 33949662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variant R94C in
    Ezekian JE; Clippinger SR; Garcia JM; Yang Q; Denfield S; Jeewa A; Dreyer WJ; Zou W; Fan Y; Allen HD; Kim JJ; Greenberg MJ; Landstrom AP
    J Am Heart Assoc; 2020 Mar; 9(5):e015111. PubMed ID: 32098556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.